The Food and Drug Administration (FDA) plays a crucial role in implementing the BPCA. The FDA identifies gaps in pediatric drug knowledge and issues written requests to pharmaceutical companies to conduct studies. The FDA also reviews the study data submitted by companies to ensure it meets regulatory standards for safety and efficacy before granting the six-month exclusivity extension.
